CDC and FDA release Beyfortus for infant RSV shortage
The U.S. CDC and FDA released over 77,000 doses of Beyfortus, a long-acting monoclonal antibody for infants too young for RSV vaccination, to address a nationwide shortage. The doses will be distributed immediately through federal programs and commercial channels. The CDC is working to make the shots more accessible for doctors. Beyfortus is prioritized for high-risk infants, while an alternative, Synagis, is recommended for older children. This is the first RSV season Beyfortus is available.